Chris Schade
CEO,
Halda Therapeutics
United States
Chris Schade is President and CEO of Halda Therapeutics. He has more than 20 years of public and private pharmaceutical and biotechnology industry experience.
Prior to joining Halda, Chris was a Growth Partner at Flagship Pioneering. Previously, he was President, CEO and Board member of Aprea Therapeutics (Nasdaq: APRE) through the company’s IPO in 2019, serving as Chairman from 2020 to 2023. Chris has also served in executive leadership positions at other biotech companies with emerging clinical candidates including: CEO of Novira, a privately held antiviral drug discovery company, until it was acquired by Johnson & Johnson; CFO Officer of Omthera Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceuticals company until it was acquired by AstraZeneca Plc; and, Senior Vice President of Administration and CFO at Medarex, Inc. until it was acquired by Bristol-Myers Squibb. Earlier in his career, Chris was Managing Director at Merrill Lynch in London and for nearly 20 years held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase.
He received an A.B. degree from Princeton University and received an MBA from the Wharton School at the University of Pennsylvania.
Suffix
MBA
Sessions
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}